We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byClare Preston
Modified about 1 year ago
Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. Presentation to FDA Advisory Committees July 30 th 2007 J. Rick Turner, PhD Chairman and Associate Professor, Department of Clinical Research Campbell University School of Pharmacy and President, Turner Medical Communications LLC Views expressed are those of the author and Turner Medical Communications LLC and not necessarily those of Campbell University.
Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. The Benefit-risk Balance No drug is immune from possibility of unwanted responses, and a drug’s safety profile must therefore be evaluated in conjunction with its efficacy/effectiveness. Benefit-risk assessments are critical components of: Regulatory decisions affecting many patients. Clinical decisions affecting individual patients.
Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. Inman and Weber (1986) “Risk-benefit judgements are complex…Irresponsible reporting by the lay press frequently leads to political pressure to restrict or ban drugs…The continued use of many valuable drugs must depend on the ability of the monitoring and regulatory agency to withstand criticism. Their policy on the whole is to warn about dangers rather than ban drugs because of them.” Inman, W.H.W. and Weber, J.C.P, 1986, The United Kingdom. In Inman, W.H.W. (Ed), Monitoring for Drug Safety, 2 nd Edition. Lancaster, UK: MTP Press/Kluwer Academic Publishers Group, p. 39. (13-47)
Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. FDA Guidance for Industry: RiskMAPs (2005) “ FDA views risk management as an iterative process encompassing the assessment of risks and benefits, the minimization of risks, and the maximization of benefits.” FDA Guidance for Industry, March 2005: Development and Use of Risk Minimization Action Plans.
Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons, Inc., All Rights Reserved. Institute of Medicine (2007) “The role of the regulator is not to impede the development of innovative medicines, but to ensure that needed drugs are available to patients and that risk-benefit information is accurate and widely available.” Institute of Medicine of the National Academies, 2007, The Future of Drug Safety: Protecting and Promoting the Health of the Public. Washington DC: The National Academies Press, p. 146-7.
24-04 Excerpted from Meggs’ History of Graphic Design, Fourth Edition. Copyright 2005, All rights reserved. Published by John Wiley & Sons, Inc.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Integrating Compliance with Business: Developing and Implementing the Tysabri Risk Map Reintroduction of a Breakthrough Medical Product November 09, 2006.
2 “The label is the most important product that a company’s research arm produces…” Essence of Licensure Conveys the Use of the Product Describes Efficacy.
Adaptive Licensing UK. Content What is adaptive licensing? Draft criteria for pilot candidate selection EMA Road Map 2015 and work programme 2012 UK perspective.
1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Safety Studies (PASS)
2 - 1 Introduction to US Health Care Text by Dennis D. Pointer, Stephen J. Williams, Stephen L. Isaacs & James R. Knickman with Tracy Barr PowerPoints.
Chapter 6 CRISIS MANAGEMENT. Introduction - Crisis: ◦is a situation that specifically involves a pharmaceutical product, medical device or activity with.
Agencies of the Executive Branch Decisions made by any agency of the Executive Branch are considered an executive order and have the power of LAW!!!
FDA Risk Communication Nancy M. Ostrove, PhD Senior Advisor for Risk Communication Risk Communication Advisory Committee February 28, 2008.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
1 Improving the agenda for SWITCH for nonprescription Medicines Sheila Kelly WSMI September 2015.
Lecture #4 Risk Assessment, philosophical approaches to risk & regulation.
1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.
Pharmacovigilance – Patient’s standpoint Steve Arlington May 2007.
The National Registration and Accreditation Scheme and what it Means for the Health Workforce Martin Fletcher, Chief Executive Officer
CONFERENCE SERIES LLC CONFERENCES Conference Series LLC is a pioneer and leading science event organizer, which publishes around 500 open access journals.
IRB-Investigator/ Research Coordinator Mtg. “CUMC’s New Progressive Policy For Adverse Event Reporting” April 13, 2004 George Gasparis Andrew Wit, Ph.D.
Introduction to US Health Care Text by Dennis D. Pointer, Stephen J. Williams, Stephen L. Isaacs & James R. Knickman with Tracy Barr PowerPoints by Robin.
AAHRPP ACCREDITATION (Association for the Accreditation of Human Protection Programs)
Risk Management Strategy for the Pharma and Biotech Product Lifecycle : New Regulatory and Legal Focus and Approach Morgan, Lewis & Bockius, LLP August.
Drug Transfer Into Breast Milk and Interpretation of Data Lawrence J. Lesko Office of Clinical Pharmacology and Biopharmaceutics Center for Drug Evaluation.
HSCI 678 Intro to US Health System Organization of the US Health Services System Chapter 4 T L Koehlmoos, PhD, MHA Adjunct Professor.
International Regulatory Capacity Building Global Curriculum Project.
Cap.org v. FNL FDA: Challenges to Protecting Public Health – Pathology’s Perspective Roger D. Klein, M.D., JD, F.C.A.P. March 7, 2013 Advocacy.
Pharmacovigilance Programme of India YK GUPTA National Coordinator, Pharmacovigilance Programme of India Prof. & Head, Department of Pharmacology AIIMS,
1 Eric G. Campbell, Ph.D. Assistant Professor Harvard Medical School Massachusetts General Hospital Commercialization in Academe: Lessons from the Life.
Emerging SACHRP Issues K. Lynn Cates, MD Assistant Chief Research & Development Officer Director, PRIDE Office of Research & Development Department of.
Ethical issues with the regulatory use of gene expression data Benjamin S Wilfond MD Medical Genetics Branch National Human Genome Research Institute Department.
FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.
Copyright 2004 John Wiley & Sons, Inc Information Technology: Strategic Decision Making For Managers Henry C. Lucas Jr. John Wiley & Sons, Inc Dinesh.
Government Regulatory Agencies and Impact on Consumer Choices Presentation.
CHAPTER 10 DATA COLLECTION METHODS. FROM CHAPTER 10 Copyright © 2003 John Wiley & Sons, Inc. Sekaran/RESEARCH 4E.
Mary Ellen Turner MD, MPH Vice-President Global Safety Surveillance & Epidemiology Risk Management: Practical Implications for Pharmaceutical Manufacturers.
To get better and go home as soon as possible. To be satisfied with the service provided. To be treated with dignity and their privacy respected.
Risk Assessments: Patient Safety and Innovation Innovation Discussion 02 July 2013.
A. Short term problems / considerations b. Long term mission View of human subjects protection system: SACHRP July 2008 Elizabeth Bankert.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Consideration of Issues John M. Kane, MD Chairman, Department of Psychiatry The Zucker Hillside Hospital The North Shore–Long Island Jewish Health System.
Chapter 17 Food Safety. Copyright 2010, John Wiley & Sons, Inc. Food Safety Talk Foodborne illness: any illness that is related to the consumption of.
Chapter 2 Standards for Electronic Health Records McGraw-Hill/Irwin Copyright © 2009 by The McGraw-Hill Companies, Inc. All Rights Reserved.
The Value of Tissue Banks to Drug and Dx Developers Barbara L. Handelin, Ph.D. Conflicts of Interest, Privacy/Confidentiality, and Tissue Repositories:
Advanced Engineering Mathematics by Erwin Kreyszig Copyright 2007 John Wiley & Sons, Inc. All rights reserved. Page 334.
Schermerhorn- Chapter 61 Management, 6e Schermerhorn Prepared by Cheryl Wyrick California State Polytechnic University Pomona John Wiley & Sons, Inc.
Advanced Engineering Mathematics by Erwin Kreyszig Copyright 2007 John Wiley & Sons, Inc. All rights reserved. Page 602.
The Accelerating Pace of Medical Development and Challenges in Evaluating Benefit and Risk Alasdair Breckenridge Medicines and Healthcare products Regulatory.
Nonprescription Simvastatin in the United Kingdom Michael L. Koenig, Ph.D. Interdisciplinary Scientist Division of Over-the-Counter Drug Products Center.
REGULATORY CHALLENGES FOR NANOMATERIALS IN PUBLIC HEALTH Driving Faster Than Our Nano-Headlights AAAS Annual Meeting February 13, 2009 Norris E. Alderson,
FDA’s Policies, Procedures, and Systems: Effects on Provider and Information Technology Sectors Karen M. Becker, Ph.D. and Philip J. Phillips, MBA Becker.
© 2017 SlidePlayer.com Inc. All rights reserved.